natgillin/translations-raw huggingface dataset:
In one embodiment, the first binding domain of the binding molecule of the invention comprises a VH region comprising CDR-H1, CDR-H2 and CDR-H3 and a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from the group consisting of: 
Vezujuća molekula prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što prva vezujuća domena sadrži VH regiju koja sadrži CDR-H1, CDR-H2 i CDR-H3 i VL regiju koja sadrži CDR-L1, CDR-L2 i CDR-L3 odabrane iz skupine koja sadrži:
To further illustrate without limiting the invention an embodiment of R9 is hydrogen; another embodiment of R9 is halogen, such as fluoro. 
Za daljnju ilustraciju bez ograničavanja ovog izuma jedna verzija R* je vodik; daljnja verzija R? je halogen poput fluora.
It will be understood that the specific dose level and frequency of dosage for any particular subject can be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition. 
Shvatit će se da specifični nivo doze i učestalost doziranja kod bilo kojeg pojedinog subjekta može varirati i ovisiti će o različitim faktorima što uključuje specifične spojeve koji se upotrebljavaju, metaboličku stabilnost i dužinu djelovanja upotrijebljenog lijeka, vrsti, dobi, tjelesnoj masi, općenitom stanju, spolu i prehrani subjekta, načinu i vremenu unosa,
Use according to any one of claims 1 to 4, wherein the metallic nanoparticle comprises a surface component enabling specific targeting of biological tissues or cells. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu nanočestica obuhvaća površinsku komponentu koja omogućuje specifično ciljanje bioloških tkiva ili stanica.
More particularly, when one of the groups R3 or R4 of the amine NHR3R4 is substituted by a hydroxy function, the latter may be subjected beforehand to a protection reaction prior to any coupling with the carboxylic acid formed from the compound of formula (IV), or with a corresponding acid derivative thereof, the resulting protected compound of formula (I) subsequently undergoes a deprotection reaction and is then optionally converted into one of its addition salts with a pharmaceutically acceptable acid or base. 
Postupak u skladu s patetnim zahtjevom 10, za pripravu spoja formule (I) pri čemu je jedna od skupina Rs ili Ry supstituirana hidroksi funkcijom, naznačen time, da se amin NHR3R, prethodno podvrgne reakciji zaštite hidroksilne funkcije prije bilo kakvog povezivanja s karboksilnom kiselinom dobivenom iz spoja formule (IV) ili s HR P20181333 T1 njezinim odgovarajućim kiselinskim derivatom, dobiveni zaštićeni spoj formule (I) naknadno prolazi kroz reakciju uklanjanja zaštite 1 zatim se može pretvoriti u jednu od njegovih adicijskih soli s farmaceutski prihvatljivom kiselinom ili bazom.
Regardless of the multiple designs of the finishing plates and component-holder plates, it must be said that all the available models are characterised in that the front of the components and relevant framing plate protrude from the installation wall, thus interrupting the clean design of the wall with a projecting element that can be hardly camouflaged or hidden. 
Bez obzira na raznolike izvedbe završnih ploča i ploča koje nose komponente, mora se reći da su svi raspoloživi modeli karakteristični po tome što prednja strana komponenti i odgovarajuće ploče okvira strše iz zida na kojemu je instalacija, dakle prekida se čisti dizajn zida s elementom koji je izbočen i kojega se teško može kamuflirati ili sakriti.
The residue was chromatographed on silica gel (5% to 10% diethyl ether:cyclohexane) to give the title compound (3.39 g, 34%) as a pale yellow oil which was a mixture of diastereomers. 
Ostatak so kromatografira na silikagelu (5 % do 10 % dietil-eter/cikloheksan) kako bi se dobilo naslovni spoj (3,39 g, 34 %) u obliku blijedožutog ulja, koje je smjesa dijastereomera.
The system of claim 1, wherein said controlling server is further configured to record the status of the events occurring and to relay such status to at least one of: said accepting appliance and said presenting appliance. 
Sustav u skladu s bilo kojim od patentnih zahtjeva 2 do 5, naznačen time što navedeni kontrolni server (101) je dodatno konfiguriran za bilježenje statusa događanja, te za slanje takvog statusa najmanje jednom od: navedene prijemne naprave (109) i navedene naprave za prikazivanje (108).
Said prodrugs are usually inactive derivatives of the parent compounds which are converted to the active forms in vivo. 
Navedeni predlijekovi obično su inaktivni derivati osnovnih spojeva, koje se in vivo prevodi u aktivne oblicke.
a DNA that hybridizes with a DNA comprising the nucleotide sequence complementary to SEQ ID N°1 and encodes a protein having a fructosyl-transferase activity; and 
(b) DNA koja hibridizira s DNA koja ima nukleotidni slijed komplementaran onom u SEQ ID NO:1 i kodira protein s aktivnošću fruktozil-transferaze; i
The lower part 4 and the upper part 6 comprises handling indentations 30 which the user may use when the packaging is to be opened like a book. 
Donji dio 4 i gornji dio 6 imaju nazubljenja 30 za zahvaćanje rukom koja može korisnik upotrijebiti kada on treba otvoriti pakiranje kao knjigu.
HCl. It is then extracted with tetrahydrofuran (2x10 mL). 
To se zatim ekstrahira tetrahidrofuranom (2 x 10 ml).
The compound according to claim 9 wherein R1, R2, R3 are hydrogen; 
Spoj u skladu s patentnim zahtjevom 7, naznačen time, da su R1, R2 i R3 vodik; n je 0;
Apart from nozzle arrangements, this problem arises for other microfluidic arrangements which have no direct nozzle function, for example filter arrangements or distribution arrangements. 
Neovisno o napravama s mlaznicom, taj problem se pojavljuje i kod drugih mikrofluidnih naprava koje nemaju izravno funkciju mlaznice, na primjer filtarske naprave ili naprave za razdiobu.
The solid oral formulation of claim 1, wherein the formulation is a capsule selected from the group consisting of: 
100 18. Kruta oralna formulacija prema zahtjevu 1, naznačena time što je formulacija kapsula odabrana iz skupine koja sadrži:
a pyrrolidinyl group substituted by C1-6 alkyl group(s) optionally substituted by C1-6 alkoxy group(s), 
pirolidinil-skupina supstituirana s jednom ili više C1-6 alkil-skupina koje su opcijski supstituirane s jednom ili više C1-6 alkoksi-skupina,
A paper roll for industrial and domestic usage, characterized in that it consists of a sequence of mutually associated disposable paper sheet according to one or more of the preceding claims. 
Rola papira za primjenu u industriji i kućanstvu, naznačena time, da se sastoji od slijeda listova papira prema jednom ili više od prethodnih patentnih zahtjeva, međusobno povezanih jedan s drugim i postavljenih tako da se mogu zasebno odijeliti kako bi se mogli odvojeno odbaciti.
A fast disintegrating dosage form in the form of a tablet according to claim 14, wherein the tablet has a hardness in the range from 40 to 100 N and a corresponding tensile strength in the range of 0.4 to 1.3 MPa. 
Brzo razgradiv oblik doziranja u obliku tablete prema zahtjevu 13, naznačen time, da tableta ima tvrdoću u rasponu od 40 do 100 N 1 odgovarajuću vlačnu čvrstoću u rasponu od 0,4 do 1,3 MPa.
The method of claim 25, wherein the patient is provided treatment, and the method further comprises the steps of obtaining one or more patient samples to determine the effect of the treatment, and continuing treatment until the hematologic malignant neoplastic disorder is reduced or eliminated. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu je subjektu osigurano liječenje, a metoda dalje obuhvaća korake dobivanja jednog ili više uzoraka od subjekta kako bi se odredio učinak liječenja te daljnje liječenje do smanjenja ili uklanjanja akutne mijeloične leukemije (AML).
The pharmaceutical formulation of embodiment 12, wherein said formulation is in the form of a tablet, a pill, powder, a capsule, syrup, an emulsion or a microemulsion. 
Farmaceutska formulacija u skladu s patentnim zahtjevom 19, pri čemu je navedena formulacija u obliku tablete, pilule, praška, kapsule, sirupa, emulzije ili mikroemulzije.
the first clade is not clade 0; or 
(c) prvi klad nije skupina 0; ili
The protective layer and/or the decorative layer may cover the whole and or a part of the inner and/or outer surface. 
Zaštitni sloj i/ili dekorativni sloj može prekrivati cijelu unutarnju i/ili vanjsku površinu ili dio unutarnje i/ili vanjske površine.
• a duct (32), through which the carbon black coming from the cyclones (17) and (18) is inserted in the turbo-mixer (29); 
. kanal (32), kroz koji čađ izlazi 1z ciklona (17) 1 (18) se ubacuje u turbo mješalicu (29);
In another embodiment, the compounds of Formula I are administered orally to the patient in need of treatment at a daily dose of about 3 to 30 mg/day, more preferably about 3 to 15 mg/day, even more preferably 5 mg/day. 
Spoj za uporabu sukladno bilo kojem od patentnih zahtjeva 1 ili 5 do 7, naznačeno time, da je navedeni spoj primijenjen u dnevnoj dozi od oko 3 do oko 30 mg/dan. Spoj za uporabu sukladno patentnom zahtjevu 8, naznačeno time, da je navedeni spoj primijenjen u dnevnoj dozi od oko 3 do oko 15 mg/dan.
An antibody-drug-conjugate of the following formula (I): 
Konjugat lijeka 1 antitijela sljedeće formule (I):
Ulipristal acetate, or any metabolite thereof, for use in treating or preventing a tumour derived from leiomyomata according to claim 1 or 2, wherein said tumour derived from leiomyomata is selected from the group consisting of leiomyosarcoma, leiomyomatosis and metastatic leiomyoma. 
Ulipristal acetat (17a-acetoksi-11B-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida.
The compactin sample (30 g) was suspended in isopropanol (5 times by volume) and heated to reflux. 
Uzorak kompaktina (30 g) je suspendiran u izopropanolu (u 5 puta većem volumenu) i zagrijan do refluksa.
The method of item 1, wherein the transfer hydrogenation is conducted in the presence of a hydrogen donor. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se hidrogeniranje prijenosom provodi u prisutnosti donora vodika.
According to an advantageous embodiment, at most approximately 5 cc of physiological saline is introduced, and it is sufficient to take a sample of approximately 1 cc. 
U skladu s ostvarenjem koje se može preporučiti, ono iznosi toliko da se unese najviše približno 5 cm" fiziološke otopine, i da se uzme uzorak od približno 1 cm.
administering a cell which expresses an exogenous protein comprising extracellular domain of human ILT7 and an exogenous molecule which is associated with human ILT7 to immune animals; and 
(1) unošenje u jednu imunu životinju stanice koja izražava egzogenu bjelančevinu koja sadrži izvanstaničnu domenu humanog ILT7 i jednu egzogenu molekulu koja se povezuje s humanim ILT7; i
The process according to anyone of claims 1 to 8, wherein said compound of Formula III is present at an amount varying from about 0.5 to about 50 moles per mole of compound of Formula II. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni spoj formule III dolazi u rasponu količina od otprilike 0,5 do otprilike 50 mol/mol spoja formule II.
The removable protective layer is removed prior to application, and may consist of the material used for the backing layer described above, provided that it is rendered removable, for example, by a silicone treatment. 
Uklonjivi zaštitni sloj se uklanja prije primjene, a može se sastojati od materijala korištenog za sloj podstave koji je opisan gore, pri čemu se mora osigurati da je izveden tako da se može ukloniti, na primjer, tretiranjem silikonom.
PTA-11267, and a light chain variable region consisting of the amino acid sequence of the light chain variable region of an antibody produced by a hybridoma deposited under ATCC Accession No. PTA-11267. 
PTA-11267, te varijabilnu regiju lakog lanca koja se sastoji od sekvence amino kiseline varijabilne regije lakog lanca antitijela proizvedenog hibridomom koje je pohranjeno u Američkoj kolekciji tipova kulture (American Type Culture Collection - ATCC) Acesijski Br.
The method of Claim 9 which uses a trap device for controlling an invertebrate pest, the trap device comprising the bait composition and a housing adapted to receive said bait composition, wherein the housing has at least one opening sized to permit the invertebrate pest to pass through the opening so the invertebrate pest can gain access to said bait composition from a location outside the housing, and wherein the housing is further adapted to be placed in or near a locus of potential or known activity for the invertebrate pest. 
Metoda iz patentnog zahtjeva 8, koja koristi klopku za kontrolu štetnika beskralježnjaka, klopka obuhvaća smjesu u obliku mamca i kućište prilagođeno prihvaćanju navedenog mamca, pri čemu kućište ima barem jedan otvor veličine koja dozvoljava štetnicima beskralježnjacima prolaz kroz otvor tako da štetnici beskralježnjaci mogu pristupiti navedenom mamcu iz smjera izvan kućišta, i gdje je kućište nadalje prilagođeno za smještaj u blizini lokaliteta moguće ili poznate aktivnosti štetnika beskralježnjaka.
ASSAY PROTOCOL FOR DETERMINING RECEPTOR BINDING FOR RUP2S: 
Protokol ispitivanja za određivanje vezivanja na receptor za rup25
differential scanning calorimetry with an endothermic event at about 160ºC; 
Diferencijalna pretražna kalorimetrija s endotermnim pomakom na oko 160°C;
A method of activating T-cells of a patient with cancer comprising administering an antigen binding domain that binds to human TIGIT (SEQ ID NO:97) to said patient, wherein said antigen binding domain comprises: 
Pripravak koji sadrži domenu vezanu antigenom koja se veže na ljudski TIGIT (SEQ ID NO: 97) koji sadrži:
A pharmaceutical composition comprising one or more compounds according to any one of E1-13 and a pharmaceutically acceptable carrier or diluent. 
Farmaceutska kompozicija koja sadrži jedno ili više spojeva u skladu sa bilo kojim od patentnih zahtjeva 1-11 i farmaceutski prihvatljiv nosač ili razblaživač.
An integral metal end cap according to claim 1 wherein the openings are oblong. 
Integrirani metalni poklopac u skladu s prethodnim patentnim zahtjevom, naznačen time, da su otvori duguljasti.
The applicable acids include, but are not limited to mineral and organic acids. In method D, Compound 10 is converted directly to Compound 6 by reacting 10 with malonic acid in a suitable solvent or solvent mixture (e.g., hydrocarbon solvent including halogenated solvent, aromatic solvent and nitrogen-containing solvents). 
. Postupak u skladu s patentnim zahtjevom 26, naznačen time što navedeni kiselinski katalizator se bira iz skupine koju čine mineralne i organske kiseline. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni korak prevođenja Spoja 10 u Spoj 6 se sastoji u reakciji Spoja 10 s malonskom kiselinom u drugom otapalu.
Preferably, binding of IL-18BP is carried out at pH 8.5±0.1, preferably in 50 mM sodium phosphate and 0.5 M NaCl having this pH. 
Poželjno, vezanje IL-18BP se provodi kod pH 8.5+0.1, poželjno u 50 mM natrij fosfatu i 0.5 M NACI s istim pH.
The antibody or fragment thereof of claim 1, wherein the antibody or fragment thereof comprises a non-CDR region of a light chain variable region sequence which is at least 80% identical to the non-CDR region of the light chain variable region sequence of SEQ ID NO: 8. The antibody or fragment thereof of claim 1, wherein the light chain sequence comprises a non-CDR region which is at least 80% identical to the non-CDR region of the light chain variable region sequence of the light chain sequence selected from the group consisting of SEQ ID NO: 45, 46, 47 or 49. 
Protutijelo ili njegov fragment sukladno patentnom zahtjevu 1, naznačeno time da, protutijelo ili njegov fragment sadrži sekvencu promjenjive regije lakog lanca koja sadrži aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEK ID BR: 8, 60, 56, 87 1 89; ili ne-CDR regiju sekvence promjenjive regije lakog lanca koja je najmanje 80% istovjetan ne-CDR regiji sekvence promjenjive regije teškog lanca odabranom iz skupine koja sadrži SEK ID BR: $, 60, 86, 87 189.
Organic layer was separated and washed with 5% citric acid, saturated sodium bicarbonate, water, and dried over sodium sulfate. 
Organski sloj je odvojen i ispran 5%-tnom limunskom kiselinom, zasićenim natrijevim bikarbonatom i vodom te je osušena pomoću natrijevog sulfata.
the VH region consists of the amino acid sequence shown in SEQ ID NO. 
(a) VH područje se sastoji od aminokiselinskog slijeda prikazanog u SEQ ID NO.
and pharmaceutically acceptable salts of compounds of Formula (I), and at least one pharmaceutically acceptable excipient for use in a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by orexin receptor activity. 
Barem jedan kemijski entitet i barem jedna farmaceutski prihvatljiva pomoćna tvar za upotrebu prema zahtjevu 8, gdje je spomenuta bolest, poremećaj ili medicinsko stanje poremećaj spavanja sekundaran Alzheimerovoj bolesti.
Drugs particularly suitable for delivery via lozenges of the invention are drugs for which the first pass effect is not beneficial, ie drugs of which the potency is reduced as a result of metabolism in the liver. 
Lijekovi koji su poželjno pogodni za primjenu preko tableta prema izumu su lijekovi na koje negativno utječe efekt prvog prolaza, tj., lijekovi čija je potentnost smanjena kao rezultat metabolizma u jetri.
Even if the supply cable were to be disconnected, the replacement operation is trivial and may be performed by anyone. 
Čak i ako se kabel za snabdijevanje električnom energijom odspoji, postupak za njegovu ponovno uključivanje je trivijalan 1 svatko ga može obaviti.
A compound of formula (I) or a physiologically acceptable solvate thereof for use in the treatment of patients according to claim 5, wherein the inflammatory and/or allergic condition is conjunctivitis. 
Spoj formule (I), ili njegov fiziološki prihvatljiv solvat, namijenjen upotrebi u liječenju pacijenata u skladu s patentnim zahtjevom 5, naznačen time što upalno i/ili alergijsko stanje je konjunktivitis.
and wherein the C-terminal amino acid is optionally amidated. An Oxyntomodulin peptide analogue according to Claim 1, comprising the amino acid sequence: wherein the Cys residue at position 38 is optionally PEGylated; and wherein the Cys residue at position 39 is optionally PEGylated; and the carboxyl group of the Cys at position 39 is optionally amidated. 
Peptidni analog oksintomodulina u skladu s patentnim zahtjevom 1, naznačen time što ima aminokiselinski slijed: His-(Aib)-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Lys-Lys-Ala-Gln-Glu-Phe-Val-Gln-Trp-Leu-Leu-Asn-(Aib)-Gly-Arg-Asn-Arg-Asn-Asn-Ile-Ala-Cys-Cys (SEQ ID NO:2) gdje Cys ostatak na položaju 38 je izborno PEGiliran; te gdje je Cys ostatak na položaju 39 izborno PEGiliran; i karboksilna skupina u Cys na položaju 39 je izborno amidirana.
is selected from the group consisting of hydroxy and methoxy; and 
R> je odabran iz skupine koja sadrži hidroksi i metoksi.
or a pharmaceutically acceptable salt of such compound for use in treating a disease, disorder or medical condition mediated by FAAH activity. A compound according to claim 25, wherein said compound is selected from the group consisting of: 
Spoj formule (I) prema zahtjevu 1; ili farmaceutski prihvatljiva sol navedenog spoja naznačen time da je za upotrebu za liječenje bolesti, poremećaja ili medicinskog stanja posredovanog aktivnošću FAAH.
In certain embodiments, the daily dosages appropriate for the compounds described herein described herein are from about 0.01 to about 2.5 mg/kg per body weight. 
(1) u dozi od oko 0,01 do 2,5 mg/kg spoja ili njegove farmaceutski prihvatljive soli ili solvata, koja se primjenjuje kao dnevna doza; ili
The underlayment of claim 1, wherein said element receiving surface (9) is one of an arcuate receiving surface and an angular receiving surface. 
Podloga u skladu s patentnim zahtjevom 1, naznačena time što je navedena površina za prihvat elementa (9) jedna od lučne prihvatne površine i kutne prihvatne površine.
Method of manufacturing the extended release tablet formulation according to any of the preceding claims 1 to 5, via a wet granulation process comprising the steps of 
Postupak priprave formulacije tablete produljenog oslobađanja u skladu s jednim od prethodnih zahtjeva 1 do 10, pomoću postupka vlažnog granuliranja, naznačen time, da sadrži slijedeće korake
or A and M are connected to each other such that the moiety: shown above in Formula I forms either a three, four, six, seven or eight-membered cycloalkyl, a four to eight-membered heterocyclyl, a six to ten-membered aryl, or a five to ten-membered heteroaryl; E is C(H) or C(R); 
ili A i M su vezani zajedno, tako da ostatak: [image] prikazan gore, u Formuli I, tvori bilo tro-, četvero-, šestero-, sedmero- ili osmeročlani cikloalkil, četvero- do osmeročlani heterociklil, šestero- do deseteročlani aril, ili petero- do deseteročlani heteroaril; E je C(H) ili C(R);
The solvent is then removed, risedronic acid isolated, and reacted with an alkali metal or ammonium hydroxide, bicarbonate or carbonate, to yield an alkali metal salt or the ammonium salt of risedronic acid. 
Otapalo se ukloni, risedronska kiselina se odvoji i stavi u reakciju sa alkalijskim metalom ili amonijhidroksidom, bikarbonatom ili karbonatom, čime se dobije sol alkalijskog metala ili amonijeva sol risedronske kiseline.
isolating the crystalline solid so formed. 
(v) izoliranje dobivene čvrste kristalne tvari.
Biotin for use according to Claim 12, characterized in that the excipients are chosen from the group consisting of talc, microcrystalline cellulose, lactose and mannose. 
Biotin prema zahtjevu 8, naznačen time da su pomoćne tvari odabrane iz skupine koja sadrži talk, mikrokristalnu celulozu, laktozu i manozu.
performing inverse-transformation on the transformation residual block including the current sub residual block, 
provođenje inverzne transformacije na rezidualnom bloku transformacije;
The device according to claim 1, wherein the polymer layer including antibiotic has a thickness up to 3 mm. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što je navedeni sloj polimera s antibiotikom (7) debeo do 3 mm.
The integrated circuit according to any of claims 1 to 13, wherein the gap is the largest of gaps which either are integer multiples of a number of consecutive PRBs that form the RBG and which are equal to or less than Nrb/Nd, where Nrb is a system bandwidth expressed as a total number of the PRBs, and Nd is a total number of DVRBs mapped to PRBs in the same frequency of a subframe, or are integer multiples of a number of consecutive PRBs that form the RBG and which are available depending on system bandwidth. 
Integrirani krug prema jednom od zahtjeva 1 do 14, naznačen time da je razmak najveći od razmaka koji su cjelobrojni višekratnici broja uzastopnih PRB-ova koji čine RBG 1 koji su jednaki ili manji od Nrb / Nd, gdje je Nrb propusnost sustava izražena kao ukupan broj PRB-ova, a Nd je ukupan broj DVRB-ova mapiranih na PRBove na istoj frekvenciji podokvira. Integrirani krug sukladno jednom od zahtjeva 1 do 14, naznačen time da je razmak najveći od razmaka koji su cjelobrojni višekratnici broja uzastopnih PRB-ova koji tvore RBG 1 koji su dostupni ovisno o propusnosti sustava.
reacting the compound with to yield the compound and reacting compound 11 with to produce the compound and 
N=-* i (11) reakciju spoja 11 sa da se proizvede spoj i
The flask was then placed in an ice-water bath and 17.6mL (241.62mmol, 4.5 eq.) 
Tikvica je tada bila stavljena u kupelj led-voda i 17.6 mL (241.62 mmol, 4.5 ekv.)